BiotechIndustryStocks.com Features Biotech Stock Update: "Training Special Forces Units to Fight Cancer" at the Insiders Corner by Michael Brush

BiotechIndustryStocks.com, a global investor website for the biotechnology sector, is pleased to offer an updated exclusive commentary on biotech stocks. The article, "Training Special Forces Units to Fight Cancer" featuring Oxigene, is part of the regular "Insiders Corner” column, by well-known financial writer and author Michael Brush. Mr. Brush also writes a weekly market column for CNBC on MSN Money. Mr. Brush has covered business and investing for the New York Times, Money magazine and the Economist Group.

Point Roberts, WA (PRWEB) October 8, 2005 -- BiotechIndustryStocks.com, a global investor website for the biotechnology sector, is pleased to offer an updated exclusive commentary on biotech stocks. The article, "Training Special Forces Units to Fight Cancer" featuring Oxigene, is part of the regular "Insiders Corner” column, by well-known financial writer and author Michael Brush. Mr. Brush also writes a weekly market column for CNBC on MSN Money. Mr. Brush has covered business and investing for the New York Times, Money magazine and the Economist Group.

www.BiotechIndustryStocks.com: Biotech and Pharmaceutical Research: an investor and industry news portal for the Biotech and Pharmaceutical sector. The Biotech and Pharmaceutical website does not make recommendations, but offers a unique free information portal to research news, exclusive articles, interviews, investor conferences and a growing list of participating public companies in the sector.

Our Current List of Biotech / Pharma Stocks: http://www.BiotechIndustryStocks.com/Research/Biotech,PharmaStocks.asp

If you would like your company to be added to our current list of Biotech / Pharma Stocks contact: news@investorideas.com

Exclusive Article:

By Michael Brush, “Insiders Corner”
Training Special Forces Units to Fight Cancer
October 06, 2005

Many investors avoid biotech stocks out of sheer habit. They were either burned by this notoriously volatile sector in the past (they are leery of money-losing companies that may have to do a dilutive financing), or they know that even analysts who master the intricacies of the science behind drug development still have a tough time picking winners.

All of these potential problems are legitimate concerns. That’s why following the insider signal is particularly useful in biotech - a group that can provide handsome returns when you select the right plays.

One of these might be Oxigene (OXGN), a tiny cancer treatment research company. Oxigene has multiple Phase I and Phase II tests that are yielding positive results, and the company has strong financials. It’s also targeting life-threatening diseases for which there are few treatments – exactly the kinds of therapies that the Food & Drug Administration is more likely to approve.

Full article: http://investorideas.com/insiderscorner/Articles/Fight_Cancer.asp

Featured company: Aethlon Medical, Inc.

Aethlon Medical, Inc. (OTCBB: AEMD) (Corporate Profile, News and Info) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body.

Read the exclusive InvestorIdeas.com Feature "The Insiders Corner," a weekly feature by well-known financial writer and author Michael Brush. http://investorideas.com/insiderscorner/

Disclaimer: Michael Brush may hold long or short positions in any of the stocks mentioned in this article and those positions can change at any moment.

InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp, InvestorIdeas is not affiliated or compensated by the companies mentioned in this article. Michael Brush is a freelance writer. The site is currently compensated for by its "featured companies." (AEMD) Aethlon Medical, Inc. - Three thousand dollars per month, plus restricted shares equivalent to five thousand dollars per month. http://www.homelanddefensestocks.com/Companies/AethlonMedical/Default.asp

Contact:
Dawn Van Zant 800-665-0411
Email: dvanzant@investorideas.com
Web Site: http://www.InvestorIdeas.com

# # #